CDMO News and Research

RSS

Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar program from Enzene

Adalvo today announced the acquisition of a romiplostim biosimilar program referencing Nplate® from Enzene, strengthening its biosimilars portfolio and accelerating the company’s expansion into complex biological medicines.

From Adalvo 28 Oct 2026

Alcami announces promotion of Robert Tragas to Vice President, Laboratory Services

Alcami, a leading contract development and manufacturing organization (CDMO), today announced its strengthening of laboratory leadership with the promotion of Robert Tragas to Vice President, Laboratory Services.

28 Oct 2026

Prolific announces major new investments and partnerships with NantWorks and Zylidac Bio CDMO

On the heels of our exciting major investment and Nantworks partnership announcement last week, Prolific Machines is pleased to announce a great new partnership with Zylidac Bio, a fully integrated biologics CDMO located next door to us in San Francisco Bay Area, to scale up the production of Prolific's Optogentics-enabled cell lines for clinical and GMP manufacturing!

From Prolific Machines, Inc. 28 Oct 2026

Zylidac Bio and Prolific Machines partner to scale Prolific’s next-generation biologics manufacturing platform to GMP production

Zylidac Bio, a fully integrated biologics CDMO within the Zydus Lifesciences Limited (Zydus) group, and Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions delivering breakthrough yields, superior on-target quality, and precise process control, today announced a partnership to scale Prolific's platform from early development through GMP production.

From Zylidac Bio LLC 22 Oct 2026

Touchlight announces leadership transition, with Will Downie appointed interim CEO

Touchlight today announces that Karen Fallen is stepping down as CEO and that the Board of Directors has appointed Will Downie as Interim Chief Executive Officer.

From Touchlight 21 Oct 2026

Developing biomaterials for soft tissue reconstruction

Explore how biomaterials and additive manufacturing support medical device development for soft tissue reconstruction.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 13 Oct 2026

ESTEVE CDMO expands U.S. capacity with additional $17.5 million investment in Morton Grove

ESTEVE CDMO, a global pure-play CDMO specializing in the development and manufacture of small-molecule APIs and pharmaceutical intermediates, has approved an additional $17.5 million capacity expansion and containment capabilities at its Morton Grove, Illinois facility, bringing total announced investment at the site to $33 million.

From ESTEVE CDMO 5 Oct 2026

OnDosis and Adare Pharma Solutions announce strategic collaboration to advance OnDosis's lead U.S. ADHD program

OnDosis AB ("OnDosis"), a Swedish life science company developing drug device combinations for precision dosing of oral solid medicines based on the Dosage Manager device platform, and Adare Pharma Solutions ("Adare"), a technology-driven, integrated contract development and manufacturing organization (CDMO), today announced a strategic collaboration.

From OnDosis AB 1 Oct 2026

EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy program for epilepsy ahead of first-in-human trial

EpilepsyGTx, a biotechnology company developing gene therapies for refractory epilepsy, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (AAV) gene therapies, today announced a partnership to support production of EpilepsyGTx's lead investigational gene therapy program targeting patients with focal refractory epilepsy (FRE), EPY201, ahead of first-in-human clinical trials.

From EpilepsyGTx 9 Sep 2026

Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing.

14 Jul 2026

Evonik invests US$100 million to upgrade its U.S. drug substance contract manufacturing site

Evonik is making a significant investment to strengthen manufacturing capabilities at its Lafayette (Tippecanoe), Indiana facility.

From Evonik 14 Jul 2026

Insilico Medicine founder to highlight sustainable longevity at BIO Asia-Taiwan

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend BIO Asia-Taiwan, which will be held from July 15 to 19 in Taiwan, China.

11 Jul 2026

Hovione and IDC Intranasal Drug Delivery Platform available for commercial partnerships

Hovione, a global integrated specialist CDMO, and Industrial Design Consultancy Ltd (IDC), an international product development company, today announced that their Intranasal Drug Delivery Platform has reached a new milestone, with its lead single-use nasal dry powder device now available for commercial partnerships.

From Hovione 11 May 2026

Northumbria University spinout earns CE mark for breath sampling device

A medical device company spun out of Northumbria University has reached a significant milestone — receiving CE marking for a breath sampling platform that peer-reviewed research has demonstrated can reliably collect saliva-free exhaled breath condensates (EBC) from the deep lung, making it the first technology of its type to achieve this distinction.

2 Apr 2026

LGM Pharma expands U.S. manufacturing, bringing total investment to $15M across Texas and Colorado sites

LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug product lifecycle, today announced the second phase of its CDMO growth strategy, committing an additional $9 million to its facilities in Rosenberg, Texas, and Colorado Springs, Colorado.

From LGM Pharma 19 Mar 2026

Sartorius launches next-generation platform to boost efficiency in cell therapy production

The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies.

From Sartorius 18 Mar 2026

mAbxience selects Genedata Bioprocess to automate end-to-end CDMO workflows

Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess® enterprise platform to structure and harmonize all bioprocess development data across its operations.

From Genedata AG 11 Mar 2026

AI model accelerates antibody production and clone selection

As instigators of immunity, monoclonal antibodies are marvels of modern medicine, lab-made proteins that can treat cancers, autoimmune diseases, and many other conditions.

9 Feb 2026

New partnership aims to expand global access to sickle cell gene therapy

Caring Cross, a 501(c)(3) non-profit dedicated to improving access to advanced therapies, and Boston Children's Hospital today announced a collaboration to provide a sustainable, affordable pathway for patients to access stem cell gene therapies for the treatment of Sickle Cell Disease (SCD).

22 Jan 2026

One‑Step ADC Manufacturing Reaches 95% Yield in Under One Hour, BioDlink White Paper Reveals

A new white paper from BioDlink, From Complexity to Consistency: How CDMOs Can Unlock One-Step, High-Yield and Homogeneous ADC Manufacturing for Next-Gen Oncology, reveals an advancement in antibody-drug conjugate (ADC) manufacturing

From BioDlink 15 Jan 2026